Evidence map›Paper›PMID 42420295›Full record

Trial reportNature communications2026

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.

Van To, Niko Thio, Rebecca Castle, Sean Macdonald, Tristan Molden-Hauer, James Wells, Ryan McMahon, Mathias Bressel, Ben Tran, Arun A Azad and 11 more

Registry-linked trialAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02855203 (Stereotactic Radiotherapy and Anti-PD1 Antibody), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02855203 phase1 / phase2completednot on this map

Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours

TypeinterventionalSponsorPeter MacCallum Cancer Centre, AustraliaRan2016 to 2020Enrolled30ConditionsRenal Cell CarcinomaArmsStereotactic Ablative Body Radiosurgery (SABR), Pembrolizumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Van ToCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Van.To@petermac.org.ORCID http://orcid.org/0009-0007-4403-3217
Niko ThioCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Rebecca CastleCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sean MacdonaldCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Tristan Molden-HauerCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
James WellsFrazer Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0002-9618-6940
Ryan McMahonThe Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Mathias BresselThe Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-9718-9596
Ben TranThe Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-9124-354X
Arun A AzadThe Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-7350-5622
Daniel MoonThe Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Sree AppuCabrini Department of Urology, Monash University, Melbourne, VIC, Australia.
Lih-Ming WongDepartment of Urology, St Vincent's Health, Melbourne, VIC, Australia.
Declan G MurphyThe Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-7500-5899
Katharine CuffPrincess Alexandra Hospital, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0002-9261-3618
David PryorPrincess Alexandra Hospital, Brisbane, QLD, Australia.
Lavinia SpainThe Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Lewis AuCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Criselle D'SouzaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Criselle.DSouza@petermac.org.ORCID http://orcid.org/0000-0003-2257-6388
Paul J NeesonCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Paul.Neeson@petermac.org.ORCID http://orcid.org/0000-0002-2729-5887
Shankar SivaThe Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Shankar.Siva@petermac.org.ORCID http://orcid.org/0000-0003-2840-0658

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomarkers that predict response to combined radiation and anti-PD-1 therapy in clear cell renal cell carcinoma (ccRCC) are poorly defined. RAPPORT trial (NCT02855203) is a prospective phase I/II study of stereotactic ablative body radiotherapy (SABR) and pembrolizumab in 30 patients with oligometastatic ccRCC. The primary endpoint was safety; secondary endpoints included overall survival, time to local progression, distant progression-free survival, objective and disease control rates, duration of response and patient-reported pain. Here, we report the pre-specified exploratory translational analyses. In pre-treatment tumours, responders had greater intra-tumoural cytotoxic T cell infiltration in close proximity to tumour cells, whereas non-responders showed enrichment of immunosuppressive, TGF-β and angiogenic signatures. In peripheral blood post-treatment, responders developed a proliferative burst of activated CD8

Indexed as

Carcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsRadiosurgeryAgedAntibodies, Monoclonal, HumanizedCD8-Positive T-LymphocytesCombined Modality TherapyFemaleHumansMaleMiddle AgedProgrammed Cell Death 1 ReceptorProspective StudiesT-Lymphocytes, CytotoxicTreatment OutcomeAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 Receptor

Identifiers

PMID42420295
PMCPMC13478502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.